CENTER VALLEY, Pa., Feb. 17, 2021 /PRNewswire/ -- Today, Olympus announced a partnership with Imbio, LLC to provide physicians with the SeleCT™ QCT analysis service to evaluate patient eligibility for treatment with the Spiration® Valve System, an FDA-designated breakthrough device to treat severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The SeleCT QCT analysis service analyzes previously-taken CT images to quantify important measures of emphysema, including emphysema distribution (heterogeneity), the severity of lung tissue destruction and fissure integrity between the lobes of the lung (which has been shown to be a surrogate for collateral ventilation).i Advancing the field of QCT analysis is a critical goal for Olympus as it builds on physician, patient, and healthcare system goals for less-invasive diagnostic and therapeutic options, and it leverages the undisputed expertise and leadership Olympus has developed over the last 13 years in the field of bronchoscopic lung volume reduction (BLVR) therapy.
"Imbio is advancing the field of automated clinical imaging analysis within the respiratory space. We have been impressed with the strides they have made in incorporating artificial intelligence and deep learning techniques into patient selection software and their overall service and experience working with physicians," said Lynn Ray, Global General Manager and VP, Respiratory for Olympus. "As a reliable and non-invasive method to identify an excellent patient match, the Olympus SeleCT QCT analysis service, powered by Imbio, gives physicians an important tool to include and expand their BLVR practice, and it brings an exciting treatment option to patients who struggle to breathe because of severe emphysema."
Features of the SeleCT QCT analysis service, powered by Imbio include:
Ad Statistics
Times Displayed: 172715
Times Visited: 3121 For those who need to move fast and expand clinical capabilities -- and would love new equipment -- the uCT 550 Advance offers a new fully configured 80-slice CT in up to 2 weeks with routine maintenance and parts and Software Upgrades for Life™ included.
Fully non-invasive patient selection tool that analyzes previously taken CT images to provide physicians with patient eligibility information prior to a BLVR procedure
24-hour turnaround time from receipt of CT scan results
Full HIPAA compliance and data security
Automated workflow option availability, including direct compatibility with Picture Archiving and Communications Systems (PACS)
"It is incumbent upon caregivers to leverage the strengths of our most advanced computer algorithms where they are most helpful," Dr. Alexander Bankier, MD, PhD, Chief, Cardiothoracic Imaging Section, Vice-chair of Academic Affairs, Department of Radiology, UMass Memorial Medical Center, Boston, MA. "The SeleCT QCT artificial intelligence software is instrumental in the decision analysis that identifies patients with lower likelihood of pulmonary fissure completeness, as well as assessing emphysema severity and emphysema heterogeneity, thereby matching them to procedures that can greatly improve their quality of life."
